Boobalan Pachaiyappan
Stock Analyst at Roth Capital
(4.62)
# 200
Out of 5,142 analysts
24
Total ratings
62.5%
Success rate
38.16%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Boobalan Pachaiyappan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OVID Ovid Therapeutics | Initiates: Buy | $3 | $1.45 | +106.90% | 1 | Dec 11, 2025 | |
| CING Cingulate | Maintains: Buy | $17 → $16 | $6.09 | +162.73% | 4 | Nov 19, 2025 | |
| PYPD PolyPid | Maintains: Buy | $10 → $9 | $4.24 | +112.26% | 3 | Nov 13, 2025 | |
| CAPR Capricor Therapeutics | Maintains: Buy | $12 → $13 | $27.87 | -53.35% | 3 | Nov 12, 2025 | |
| RNA Avidity Biosciences | Initiates: Buy | $62 | $72.92 | -14.98% | 1 | Sep 17, 2025 | |
| RVPH Reviva Pharmaceuticals Holdings | Reiterates: Buy | $7 → $3 | $0.24 | +1,150.00% | 2 | Aug 18, 2025 | |
| LGVN Longeveron | Maintains: Buy | $10 → $3 | $0.57 | +430.41% | 2 | Aug 15, 2025 | |
| GANX Gain Therapeutics | Maintains: Buy | $7 → $6 | $2.09 | +187.08% | 3 | Aug 13, 2025 | |
| CRVO CervoMed | Reiterates: Buy | $20 → $16 | $4.64 | +244.83% | 4 | Aug 12, 2025 | |
| TRDA Entrada Therapeutics | Initiates: Buy | $29 | $11.29 | +156.86% | 1 | Dec 5, 2024 |
Ovid Therapeutics
Dec 11, 2025
Initiates: Buy
Price Target: $3
Current: $1.45
Upside: +106.90%
Cingulate
Nov 19, 2025
Maintains: Buy
Price Target: $17 → $16
Current: $6.09
Upside: +162.73%
PolyPid
Nov 13, 2025
Maintains: Buy
Price Target: $10 → $9
Current: $4.24
Upside: +112.26%
Capricor Therapeutics
Nov 12, 2025
Maintains: Buy
Price Target: $12 → $13
Current: $27.87
Upside: -53.35%
Avidity Biosciences
Sep 17, 2025
Initiates: Buy
Price Target: $62
Current: $72.92
Upside: -14.98%
Reviva Pharmaceuticals Holdings
Aug 18, 2025
Reiterates: Buy
Price Target: $7 → $3
Current: $0.24
Upside: +1,150.00%
Longeveron
Aug 15, 2025
Maintains: Buy
Price Target: $10 → $3
Current: $0.57
Upside: +430.41%
Gain Therapeutics
Aug 13, 2025
Maintains: Buy
Price Target: $7 → $6
Current: $2.09
Upside: +187.08%
CervoMed
Aug 12, 2025
Reiterates: Buy
Price Target: $20 → $16
Current: $4.64
Upside: +244.83%
Entrada Therapeutics
Dec 5, 2024
Initiates: Buy
Price Target: $29
Current: $11.29
Upside: +156.86%